Supplements

2014

 

  • April 2014 (Monograph mailed with RETINA)
    INDIVIDUALIZING THERAPY FOR PATIENTS WITH NEOVASCULAR AMD AND DME: CONSIDERATIONS FOR SHORT- AND LONG-TERM MANAGEMENT

Proceedings from an Experts Roundtable Discussion. Jointly sponsored by The University of Louisville Department of Continuing Education and MedEdicus. This continuing education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.

  • January 2014 (Monograph mailed with RETINA)
    MACULAR EDEMA FOLLOWING CENTRAL RETINAL VEIN OCCLUSION (CRVO): THE ROLE OF EYLEA® (AFLIBERCEPT) INJECTION

Supplement prepared and sponsored by Regeneron.

2013

CYTOKINE TRAP TECHNOLOGY AND NEOVASCULAR (WET) AGE-RELATED MACULAR   DEGENERATION: THE ROLE OF EYLEA (AFLIBERCEPT) INJECTION

Prepared and sponsored by Regeneron

 

  • April 2013 (Monograph mailed with RETINA)

    CASE DEBATES IN THE MANAGEMENT OF AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA

    Jointly sponsored by The New York Eye and Ear Infirmary and MedEdicus LLC.

    Supported through an unrestricted educational grant from Genentech, Inc.

REFINING ANTI-VEGF DOSING STRATEGIES FOR YOUR PATIENTS WITH WET AMD

Jointly sponsored by The New York Eye and Ear Infirmary and MedEdicus LLC.

Supported through an unrestricted educational grant from Genentech, Inc.

2012

  • Volume 32, September 2012, Supplement 2

VITREOMACULAR DISORDERS: PATHOGENESIS AND TREATMENT

Proceedings from a Roundtable Symposium

Supported through an unrestricted educational grant from ThromboGenics, Inc.

pp. S173-S232

 

MANAGEMENT OF DIABETIC MACULAR EDEMA APPLICATION OF CURRENT EVIDENCE TO PATIENT CARE

Highlights from a Roundtable Discussion

Supported through an unrestricted educational grant from Alimera Sciences.

 

  • May 2012 (Monograph mailed with RETINA)

ADVANCES IN THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION

Proceedings from a Roundtable Discussion

Jointly sponsored by The New York Eye and Ear Infirmary and MedEdicus LLC.        

Supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc, with additional support from Optovue, Inc.

 

TRIBUTE TO LARRY A. YANNUZZI, MD

pp. OP-893:OP-906,1-1572,S1-S28